Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HINT1 | P49773 | 3/20 | 0.45 |
| ▸ | STING1 | Q86WV6 | 9/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14512779 | 1.00 | HPGD (0.46) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL16587630 | 0.93 | HPGD (0.44) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL12646749 | 0.92 | HPGD (0.45) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL12015165 | 0.92 | HPGD (0.45) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL12590101 | 0.92 | HPGD (0.45) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL24263984 | 0.92 | HPGD (0.45) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL19840285 | 0.92 | HPGD (0.45) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL18058960 | 0.91 | HPGD (0.44) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL24429201 | 0.91 | HPGD (0.44) | HPGDHINT1STING1PDE3BPDE3A | |
| SCHEMBL27277340 | 0.89 | HPGD (0.43) | HPGDHINT1STING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | SANKYO COMPANY, LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117773-A1 | Telomerase-inhibiting ENA oligonucleotide | TERT, ENO1, TERB1 | HPGD 2529/4885HINT1 4064/4885STING1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.